This is a brand new award recognising the company with the largest percentage of citations for products used in cardiovascular research, demonstrating continued success in the cardiovascular research field.

We are thrilled to announce that Abcam has been named the CiteAb Antibody Supplier Succeeding in Cardiovascular Research.

From the data generated through CiteAb, we are able to gain a really clear picture of the way life science products are used around the world. We can tell which countries are investing most in research using these products, which suppliers are seeing growth or decline, which products are most successful and which areas of research are seeing growth.

This award was made based on our CiteAb data between January 2020 and December 2020, and celebrates Abcam as the company with the most citations for products used in cardiovascular research.

Dr Andrew Chalmers, founder of CiteAb, said: “The COVID-19 pandemic dominated last year, bus has not taken away the pressing need for research in a wide range of other disease areas, with cardiovascular research being a really key area where improved understanding can lead to improved health. Congratulations to Abcam for being named CiteAb Antibody Supplier Succeeding in Cardiovascular Research. This is a fantastic achievement, with data for the company demonstrating the huge impact it has on the cardiovascular research field. I wish the whole team at Abcam many congratulations on their win.”